Skip to main content

Advertisement

Table 5 Current commercially available genetic test for BC and their principal characteristics

From: Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential

  Author N. genes Samples used to generate BC signature Independent validation study Laboratory
MammaPrint van't Veer et al. [215] 70 − 78 BC patients − 295 early stage invasive BC. Agendia
− 302 who had received loco-regional therapy but no systemic adjuvant therapy
Oncotype DX Paik et al. [221] 21 − 447 BC patients − 668 node negative ER positive tamoxifen treated cases Genomic Health
− 651 BC samples: 227 had been randomly assigned to tamoxifen adjuvant therapy and 424 to tamoxifen plus chemotherapy
PAM50 Parker et al. [223] 50 − 189 BC patients − 761 patients (no systemic therapy), 133 (neoadjuvant chemotherapy) NanoString’s Prosigna™
Genomic Grade Index (GGI) Sotiriou et al. [4] 97 − 64 BC patients − 597 BC Ipsogen
− 55 endocrine-treated patients.
Mammostrat Bartlett et al. [225] 5 − 466 BC patients − 299 BC, 344 BC Clarient